Patent EP0152897A1 successfully refreshed from Google Patents.
EP0152897A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1985-02-12
•
Granted: —
•
Expires: 2005-02-12
Abstract
Abstract The compound, 8-chloro-6,11-dihydro -11- (4-piperidyli- dene)-5H-benzo [5,6] cyclohepta [1,2-b] pyridine, and the pharmaceutically acceptable salts thereof possess anthihis- taminic properties with substantially no sedative properties. Methods for preparing and using the compound and salts are described.
Inventors
- 👤 Frank J. Villani
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 23:00
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/04; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/81; C07D221/00; C07D221/02; C07D221/04; C07D221/06; C07D221/16
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
13 words
The compound 8-chloro-6,11-dihydro-ll-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine having the structural formula: and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
13 words
The compound 8-chloro-6,11-dihydro-ll-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine having the structural formula: and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
14 words
The compound defined in claim 1 in the form of the acetic acid salt.
Claim 4
Dependent Claim
42 words
Process for the preparation of the compounds defined in claim 1 or 2 characterized in that a) 8-chloro-6,11-dihydro-ll-(l-ethoxycarbonyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is decarbethoxylated; or b) 8-chloro-6,11-dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is demethylated followed by isolation of the compound in the free form or in the form of its salt.
Claim 5
Dependent Claim
20 words
A pharmaceutical composition which comprises the compound defined in claim 1 or 2 in combination with a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
10 words
The composition defined in claim 4 in unit dosage form.
Claim 7
Dependent Claim
3 words
CLAIMS for AT:
Claim 8
Dependent Claim
45 words
Process for the preparation of 8-chloro-6,11-dihydro-ll-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[l,2-b]pyridine having the structural formula: and the pharmaceutically acceptable salts thereof, characterized in that a) 8-chloro-6,11-dihydro-11-(1-ethoxycarbonyl-4-piperdylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is decarbethoxylated; or b) 8-chloro-6,11-didhydro-11-(1-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is demethylated followed by isolation of the compound in the free form or in the form of its salt.
Claim 9
Dependent Claim
45 words
Process for the preparation of 8-chloro-6,11-dihydro-ll-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[l,2-b]pyridine having the structural formula: and the pharmaceutically acceptable salts thereof, characterized in that a) 8-chloro-6,11-dihydro-11-(1-ethoxycarbonyl-4-piperdylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is decarbethoxylated; or b) 8-chloro-6,11-didhydro-11-(1-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine is demethylated followed by isolation of the compound in the free form or in the form of its salt.
Claim 10
Dependent Claim
20 words
Process according to claim 1, characterized in that the compound is isolated in the form of its acetic acid salt.
Claim 11
Dependent Claim
24 words
Process for the preparation of a pharmaceutical composition which comprises mixing the compound defined in claim 1 or 2 with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
15 words
Process for the preparation of the composition defined in claim 3 in unit dosage form.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.